Slamon et al trial results: TH very effective and equivalent to TCH in Stage IV her2+

[bmorr7]

Hi,

Our oncologist is recommending the TCH regimen. Does this study imply that the TH regimen would be preferred over TCH for Her-2 positive stage 1 breast cancer?

Thanks,

Ben

[Andrea Barnett Budin]

I only know TH -- and supplements -- have worked for me.

I wouldn't want to add more toxicity w/C.

Taxotere hit me hard. I didn't care. I wanted to live! I saw myself as being in a process and would walk through fire to get there. For me, Taxotere was hell. But I NEVER regret taking it, because I believe it contributed to me getting to STABLE. That was 1999. And I remain STABLE.

I did do 10 years of Vitamin H (what I affectionately call Herceptin). My onc thought 5 yrs would be enough. But I was not anxious to mess with success. If it isn't broken, why fix it???

I've been off for 5 yrs. Still STABLE...

[Jackie07]

Oncologist. 2013 Jun 28. [Epub ahead of print]
Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study.
Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ; on behalf of the Translational Research In Oncology BCIRG 006 trial investigators.
Source
Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada;
Abstract
BACKGROUND:
This study aims to describe and compare health-related quality of life (HRQL) in patients with node-positive and high-risk node-negative HER2-positive early breast cancer receiving adjuvant docetaxel and trastuzumab-based or docetaxel-based regimens alone.
METHODS:
Eligible patients (n = 3,222) were randomly assigned to either four cycles of adjuvant doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC→T) or one of two trastuzumab-containing regimens: adjuvant doxorubicin and cyclophosphamide followed by docetaxel plus trastuzumab administered for 1 year (AC→TH) or six cycles of docetaxel plus carboplatin combined with trastuzumab administered for 1 year (TCH). The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 and BR-23 were administered at baseline, the start of cycle 4 (mid), and the end of chemotherapy (EOC), as well as at 6, 12, and 24 months after chemotherapy.
RESULTS:
Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12-month assessment. Systemic side effect (SE) change scores were significantly improved for TCH-treated patients compared with AC→TH and AC→T at EOC, suggesting improved tolerability. Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC→TH regimen, but was otherwise similar between arms. All treatment arms recovered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up.
CONCLUSION:
HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option.

[Andrea Barnett Budin]

Jackie,

Hi! Trying to muddle my way through your post. Full of jargon that never fails to stymy me. However the last line I can read.

TCH is more tolerable (than TH)???

Am I reading that correctly?